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Abstract
Background: Atopic dermatitis (AD) is an inflammatory, chronically relapsing, and intensively pruritic skin disease
that affect 10–30% of the global population. Angelicae dahuricae Radix (ADR) has been reported to be anti-
inflammatory in Korean Medicine. In the present study, we investigated whether ADR suppresses the progression of
AD in animal model.
Methods: AD was induced by 2, 4-Dinitrochlorobenzene (DNCB). ADR was orally administered to mice to study
the effect of ADR on AD. Histological Analysis, immunohistochemistry, blood analysis, RT-PCR, and ELISA assay
were performed.
Results: ADR significantly suppressed AD-like symptoms in BALB/c mice: ADR decreased skin thickness and
spleen weight of mice. ADR reduced infiltration of mast cells, inflammatory cells and CD4+ cells into mouse skin.
ADR lowered the number of WBCs in the blood of mice. ADR reduced the levels of IgE, IL-6, IL-10 and IL-12 in
mice serum. ADR down-regulated mRNA expression of IL-4, IL-6 and TNF-α in mouse skin tissue.
Conclusion: Our present study clearly indicates that ADR suppresses the progression of AD induced by DNCB in
BALB/c mice. This suggests that ADR might be a useful drug for the treatment of AD.
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Background
10–30% of the global population in the world suffer by
atopic dermatitis (AD), which is also known as atopic
eczema, and is one of the most common allergic diseases
[1, 2]. AD is characterized by chronic or relapsing skin
disorder, skin barrier dysfunction, and pruritic skin
inflammation [3–5]. 2–10% of adults and 15–30% of
children suffer from AD experiencing a significant re-
duction in quality of life [6–8]. Over the past 10 years,
the prevalence of AD has increased a two-fold in elem-
entary school-aged children in South Korea [9]. Therefore,
successful treatment of AD is a very important task to
decline disease.
The pathogenesis of AD is not well known, but two
main theories have been proposed. In one theory, it was
explained that AD is associated with filaggrin gene
mutations. Filaggrin is a filament-associated protein
that binds to keratin fibers in epidermis. Defection in
filaggrin seems to induce skin barrier dysfunction
leading to water loss from the skin [10, 11]. The
other theory is immunological hypothesis associated
with Th1/Th2 imbalance. T-helper cells play an im-
portant role in disease onset and progression. There
is a predominance of Th2 cells rather than Th1.
This results in increased infiltration of inflammatory
cells such as lymphocytes and macrophages into the
skin lesions, and eosinophilia in peripheral blood.
This also induces increased level of immunoglobulin
E (IgE) [12, 13].
Surfaces of mast cells aggregate high-affinity IgE re-
ceptors (FcεI). IgE secretion is an important immedi-
ate hypersensitivity reaction in AD through mast
cells. Mast cell activation releases not only inflamma-
tory mediators but also Th2 cytokines (IL-4, IL-5 and
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IL-13) [14, 15]. Proinflammatory cytokines such as
IL-6 and IL-10 play an important role in allergic in-
flammation [16, 17]. Moreover, proliferation of CD4+
T cells is observed in AD patient [18–20].
Angelicae dahuricae Radix (ADR) is a perennial plant
that grows naturally. ADR are commonly known as
Chinese Angelica, Wild Angelica, or Bai Zhi in Chinese
[21]. ADR is known as Baig-Ji in Korean. ADR leaves are
used to make strong scented incense. In addition, ADR
are used in traditional medicine to counter harmful ex-
ternal influences on the skin, such as cold, headaches,
rhinitis, heat, dampness and dryness [22]. In the experi-
mental study, ADR alleviated the redness, swelling, and
other symptoms of acute inflammation in mouse and rat
[23]. ADR reduced the levels of the serum inflammatory
mediators including Nitric oxide (NO), Tumor Necrosis
Factor-alpha (TNF-α), and prostaglandid E2 (PGE2) [24].
ADR showed anti-inflammatory activity in RAW264.7 cell
and cytotoxic effect in A549 cells and KB cells [25]. Main
compound of ADR is known to be an aviprin [26]. Aviprin
showed antioxidant activity and is cytotoxic on LNCaP
and HeLa cell lines [27]. These results indicate that ADR
may be good candidate for the control of AD and benefi-
cial in the treatment of human allergic disorders.
In the present study, we investigated whether ADR
oral administration has anti-inflammatory activity on
2,4-dinitrochlorobenzene-(DNCB-) induced AD-like skin
lesions in mice model.
Methods
Preparation of Angelicae dahuricae Radix (ADR)
ADR was supplied by Han-poong Pharm Co., Ltd (Jeonjoo,
Republic of Korea). ADR powder was dissolved in distilled
water to give to mice a concentration of 200 mg/kg.
Animals
Animal experiments were approved by Kyung Hee
university institutional animal care of use committee
(KHUASP(SE)) and performed according to ethical
treatment. Six-week-old male BALB/c mice were pur-
chased from Orient (Seoul, Republic of Korea). Mice
were maintained for 1 week before the start of the ex-
periment. Animals were randomized and all housed
under controlled temperature (23 ± 3 °C) and humidity
(55 ± 15%), with a 12 h light/12 h dark cycle. Animals
were provided with a laboratory diet and water ad libitum.
Body weight and Food intake of animals were measured
once every 2 days.
Induction of AD and treatment
Induction of AD procedure and treatment are described
in Fig. 1. The mice were divided into three groups (n = 8):
group 1, normal; group 2, DNCB; group 3, DNCB +
ADR(200 mg/kg). For the experiment, mice back skin
was painted dermally with 200 μ L of a 2% DNCB using
1 × 1 cm patches after shaving. Three weeks after
sensitization, the back skin was challenged with 200 μL
of a 0.2% DNCB solution. Finally, mice were fed with
ADR together with DNCB sensitiazation for 2 weeks.
At the end of experiment, mice were sacrificed by CO2-
inhalation, and samples were collected.
Histological Analysis
Skin samples were embedded in Tissue-Tek optical cutting
temperature (OCT) compound (Leica, USA). The section of
the skin samples was 20 μm-thick. We used caliper to meas-
ure skin thickness. Each section was stained with
hematoxylin and eosin (H & E) for inflammatory cells and
with toluidine blue (T.B) for mast cells, and examined under
light microscopy (Olympus). Mast cells and inflammatory
cells were counted in 10 parts of high-power fields (HPF)
(250 μm x 250 μm) at 40x, 400x and 1000x magnification.
Immunohistochemistry
Expression of CD4+ lymphocytes was detected by im-
munohistochemical analysis using the anti-CD4+ antibody.
The skin tissues were rehydrated. After a microwave treat-
ment, the sections were treated with 3% hydrogen peroxide
in PBS for 15 min to inhibit endogenous peroxidase activity
of blood cells. The skin sections were blocked with 5%
bovine serum albumin (BSA) in PBS for 1 h, at room
temperature. Skin sections were incubated with mouse
monoclonal CD4+ antibody overnight at 4 °C and
subsequently incubated with secondary biotinylated anti-
rabbit IgG for 1 h at room temperature. Sections were
treated with avidin-biotin HRP complex (Vectastain ABC
Fig. 1 General schematic diagram of studies
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kit, Vector Labs, Burlingame, CA, USA) for 30 min at 4 °C
and finally stained with diaminobenzidine tetrachloride
(DAB) as a substrate. The slides were mounted with an
aqueous mounting solution (DAKO, Glostrup, Denmark)
and cover-slipped. All the sections were analyzed using an
Olympus microscope and images were captured using a
digital video camera.
Analysis of mouse blood
Whole blood samples were collected by cardiac punc-
ture. The blood was placed in Vacutainer TM tubes con-
taining EDTA (BD science, Franklin Lakes, NJ, USA).
Anti-coagulated blood was submitted to determination
of hematological parameters (WBC, lymphocytes,
monocytes, eosinophils, basophils and neutrophils) in a
HEMAVET 950 hematology analyzer (Drew Scientific,
Inc., Miami Lakes, FL, USA) in accordance to manufac-
turer’ recommendation.
RT-PCR
RNA was isolated using easy-blue RNA extraction kit
(iNtRON biotech, Seongnam, Republic of Korea) accord-
ing to the manufacturer’s instructions. Isolated RNA
content was measured using the NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies Inc, Wil-
mington, North Carolina, USA). Total cellular RNA
from each sample was reversely transcribed using cDNA
synthesis kit (TaKaRa, Otsu, Shiga, Japan). PCR was per-
formed using the specific primer. The primers used were
as follows : mouse IL-4 (Forward : 5’ - TCG GCA TTT
TGA ACG AGG TC - 3’, Reverse : 5’ - GAA AAG CCC
GAA AGA GTC TC - 3’); mouse IL-6 (Forward : 5’ - GAT
GCT ACC AAA CTG GAT ATA ATC - 3’, Reverse : 5’ -
GGT CCT TAG CCA CTC CTT CTG TG - 3’); mouse
TNF-α (Forward : 5’ - ATG AGC ACA GAA AGC ATG
ATC - 3’, Reverse : 5’ - TAC AGG CTT GTC ACT GGA
ATT - 3’); and mouse GAPDH (Forward : 5’ - GAG GGG
CCA TCC ACA GTC TTC - 3’, Reverse : 5’ - CAT CAC
CAT CTT CCA GGA GCG - 3’).
Enzyme-Linked Immune Sorbent Assay (ELISA)
For measurement of total serum IgE, IL-6, IL-10 and IL-
12, blood specimens were obtained from the heart on
the final day. The blood was placed in Vacutainer tubes
containing EDTA (BD science, Franklin Lakes, NJ, USA)
and blood plasma was isolated. Total IgE, IL-6, IL-10
and IL-12 levels in plasma were determined by sandwich
ELISA using the BD PharMingen ELISA set according
to the manufacturer’s instruction. Optical densities were
measured at 450 nm using a microplate reader (Versa
Max, Molecular Devices, Sunnyvale, CA, USA).
Statistical analysis
All quantitative data derived from this study were analyzed
statistically. One-way ANOVA was used for analysis of
our data. The results were expressed as the mean ± SEM.
Statistical significance at P < 0.05 < 0.01 and < 0.001 has
been given respective symbols in the figures.
Results
Effect of oral administration of ADR on body weight and
food intake of mice
We monitored body weight and food intake of mice
throughout the study. We observed no significant changes
in this regard, indicating that ADR may not affect general
conditions in mice (Fig. 2a and b).
Effect of ADR on DNCB-induced AD in mice model
AD-like skin lesions were induced in Balb/c mice apply-
ing DNCB for 4 weeks. DNCB application was followed
by ADR oral administration. ADR markedly inhibited
AD as shown in Fig. 3a. A histogram of skin thickness
estimated is shown in Fig. 3b. Normal skin was found to
be 0.58 ± 0.12 mm (ranging from 0.46 to 0.84 mm), while
DNCB-induced AD skin (negative control) was found to
Fig. 2 Changes in body weight (a) and Food intake (b) during treatment with ADR (200 mg/kg). After induction of AD by DNCB, mice were
orally administered with ADR. Values are expressed as mean ± SEM (n = 8)
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be 2.12 ± 0.27 mm (ranged from 1.92 to 2.66 mm). DNCB-
induced AD skin orally treated with ADR was found to be
1.23 ± 0.21 mm (ranged from 0.92 to 1.48 mm). Data dem-
onstrate that ADR decreased skin thickness of mice.
Moreover, ADR decreased spleen weight of mice (Fig. 3b).
Effect of ADR on mast cells, inflammatory cells and
CD4+ cells
To determine whether ADR reduces infiltration of mast
cells and inflammatory cells into skin, we performed T
& B staining and H & E staining on the skin samples.
Numbers of mast cells and inflammatory cells in AD
mice were shown to be higher than those in normal
mice. ADR decreased such infiltration of mast cells and
inflammatory cells into skin (Fig. 4a, c). Mast cells and
inflammatory cells numbers under each condition were
shown in Fig. 4b, d. We performed immunocytochemistry
to examine whether ADR reduces level of CD4+ (total T
cells) within skin. The level of CD4+ in DNCB-induced
AD lesions in mice is higher than that in normal mice.
ADR decreased the level of CD4+ cells within the skin
(Fig. 4e, f ).
Effect of ADR on WBCs in the blood of mice
To investigate whether ADR suppresses inflammatory
phenomenon, we measured leukocytes levels in cardiovas-
cular blood samples using HEMAVET 950 hematology
analyzer. We observed that DNCB application increased
total number of white blood cells (WBCs) and each
subtypes of WBCs including neutrophils, basophils, eo-
sinophils, monocytes, and lymphocytes in serum of
mice. Importantly, a subsequent oral administration of
ADR lowered the increased number of WBCs, implicating
ADR suppresses inflammatory responses by decreasing
the number of WBCs in the blood (Fig. 5a, b, c, d, e
and f ).
Effect of ADR on the levels of IgE, IL-6, IL-10 and IL-12 in
mice serum
We measured the levels of inflammatory cytokines in
the blood samples by ELISA assay.
We found that DNCB increased the levels of IgE, IL-6,
IL-10 and IL-12 while ADR inhibited such increases
(Fig. 6a, b, c and d).
Effect of ADR on mRNA expression of IL-4, IL-6 and TNF-α
in mouse skin tissue
To determine whether ADR decreases AD-relevant cyto-
kines expression, we performed RT-PCR to measure
levels of IL-4, IL-6 and TNF-α. We found that DNCB
increased the levels of IL-4, IL-6 and TNF-α while ADR
decreased such increases (Fig. 7a, b, c and d).
Discussion
AD is a chronic inflammatory skin disease, which in-
creases serum immunoglobulin E (IgE) levels and infil-
tration of inflammatory cellincluding mast cells and
eosinophils [28, 29]. The pathogenesis of AD is primarily
Fig. 3 Observations of skin lesions in ADR (200 mg/kg) treated DNCB-induced AD mice. The photograph shows the back of mice on day 28 after
sensitization (a). The measurement of skin thickness (b) spleen weight (c) in DNCB-induced AD mice model treated with ADR. Values are expressed as
mean ± SEM (n = 8)
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driven by Th2 immune responses [14]. This causes epider-
mal thickness of mice with cutaneous hypersensitivity.
CD4+ T cells and mast cells are known as key factors
in allergic inflammatory diseases. AD mouse model con-
tains increased CD4+ T cell [30, 31]. DNCB-induced AD
mouse model showed severe AD symptoms, increase in
mast cells, epidermal hyperplasia and elevation of serum
IgE levels. DNCB-induced BALB/c mice model repre-
sented increase of IL-4 mRNA level. BALB/c mouse is
advantageous AD model as compared to other animal
model since it develops Th2-skewed immune response
[32, 33].
In this study, we investigated the anti-AD effects of
ADR using DNCB-applied BALB/c mice. We found that
oral administration of ADR strongly suppressed DNCB-
induced AD-like symptoms such as skin thickness. Nor-
mal skin was found to be 0.58 ± 0.12 mm (ranging from
0.46 to 0.84 mm), while DNCB-induced AD skin (nega-
tive control) was found to be 2.12 ± 0.27 mm (ranged
from 1.92 to 2.66 mm). DNCB- induced AD skin orally
treated with ADR was found to be 1.23 ± 0.21 mm
(ranged from 0.92 to 1.48 mm). ADR also reduced infil-
tration of mast cells, inflammatory cells and CD4+ cells
into the sensitized skin. Numbers of mast cells and in-
flammatory cells in AD mice were shown to be higher
than those in normal mice. ADR decreased such infiltra-
tion of mast cells and inflammatory cells into skin. The
level of CD4+ in DNCB-induced AD lesions in mice is
higher than that in normal mice. ADR decreased the
level of CD4+ cells within the skin
In AD skin, activated Th2 cells would produce IgE by
releasing cytokines such as IL-4 [34, 35]. Associated Th2
inflammatory cytokine, such as IL-4 and IL-6 could pro-
mote the occurrence and development of inflammatory
reactions [19, 36, 37]. In our study, ADR application de-
creased the serum levels of IgE, IL-6, IL-10 and IL-12
that are induced by DNCB treatment. DNCB increased
the levels of IgE, IL-6, IL-10 and IL-12 while ADR
Fig. 4 ADR (200 mg/kg) reduced infiltration of mast cells, inflammatory cells and CD4+ cells into skin. The skin sections were stained with
toluidine blue (a). Sections were evaluated using microscope at an original magnification of 200x. The skin sections were stained with hematoxylin and
eosin (c). Sections were evaluated using microscope at an original magnification of 200x. The skin sections were immunostained with CD4+ antibody.
CD4+ cells were shown as brown color (e). b, d, f Sections were evaluated and graphed from the results of (a), (c), (e). Sections were evaluated using
microscope at an original magnifiation of 1000x. Data are presented as mean ± SEM. ∗P< 0.05, ∗∗P< 0.01, and ∗∗∗< 0.001
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inhibited such increases. ADR application reduced the
DNCB-stimulated increases of the number of eosino-
phils, neutrophils, monocytes, basophils, lymphocytes
and WBC. A subsequent oral administration of ADR
lowered the increased number of WBCs, implicating
ADR suppresses inflammatory responses by decreasing
the number of WBCs in the blood Moreover, ADR
reduced the levels of IL-4, IL-6 and TNF-α mRNA ex-
pression. ADR exhibited decrease in mast cell recruit-
ment and serum IgE levels. ADR reduced infiltration of
CD4+ cells into mouse skin. ADR suppressed the ex-
pression of inflammatory cytokine including IL-4, IL-6,
IL-10 and TNF-α. DNCB increased the levels of IL-4,
IL-6 and TNF-α while ADR decreased such increases.
Fig. 6 ADR (200 mg/kg) reduced the levels of cytokines in the serum. The release of IgE (a), IL-6 (b), IL-10 (c) and IL-12 (d) was measured by
sandwich ELISA assay. Data are presented as mean ± SEM. ∗P< 0.05, ∗∗P< 0.01, and ∗∗∗P< 0.001
Fig. 5 ADR (200 mg/kg) reduced the levels of leukocytes in the blood. WBC (a), Neutrophil (b), Lymphocyte (c), Monocyte (d), Eosinophil (e), Basophil
(f) were analyzed using HEMAVET 950 hematology analyzer. Data are presented as mean ± SEM. ∗P< 0.05, ∗∗P< 0.01, and ∗∗∗P< 0.001
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These results suggest that ADR suppresses skin inflamma-
tion by inhibiting the DNCB-stimulated numerous inflam-
matory responses. Moreover, free radicals are unstable
and independent but can be cause of many diseases in-
cluding cancer and atopic dermatitis. ADR seems to
act against free radicals by removing them [38, 39]
Limitations of AD model is that animal study generates
many differences from human study in terms of the ana-
tomical, physiological, and immunological contributors.
Moreover, it is difficult to establish chronic disease model
in mice. Nevertheless, AD mice model is still important
tool to investigate chronic disease for human being.
Conclusions
Our present study clearly demonstrates that ADR sup-
presses the progression of AD induced by DNCB. ADR
significantly suppressed AD-like symptoms in BALB/c
mice: ADR decreased skin thickness and spleen weight
of mice. ADR reduced infiltration of mast cells, inflam-
matory cells and CD4+ cells into mouse skin. ADR low-
ered the number of WBCs in the blood of mice. ADR
reduced the levels of IgE, IL-6, IL-10 and IL-12 in mice
serum. ADR down-regulated mRNA expression of IL-4,
IL-6 and TNF-α in mouse skin tissue. Therefore, ADR
might be a useful drug for the treatment of AD. Our
data indicates that ADR have a potential as a new drug
for the suppression of AD.
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